Mass General Brigham Health Plan Prior Authorization Lookup
- Mass General Brigham Health Plan coverage criteria
- Mass General Brigham Health Plan contact directory
- All Mass General Brigham Health Plan policy updates
Latest Mass General Brigham Health Plan prior authorization updates25
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Anti-Retroviral Agents: Sunlenca (lenacapavir) and Trogarzo (ibalizumab-uiyk)Prior authorization criteria for Sunlenca and Trogarzo under the MassHealth medical benefit for adults with heavily treatment-experienced, multidrug-resistant HIV-1.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Calcitonin Gene-Related Peptide (CGRP) Inhibitors: Vyepti (eptinezumab-jjmr)This policy governs prior authorization and continuation of Vyepti (eptinezumab-jjmr) under the medical benefit for adult members receiving preventive treatment for migraine, including MassHealth UPPL coverage, clinical criteria, documentation, step therapy, and continuation requirements.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Colony-Stimulating FactorsThis policy governs prior authorization for selected granulocyte colony-stimulating factors covered under the medical benefit for MassHealth members. It establishes indication, preferred-product failure or contraindication, medical-necessity, dosing, continuation, and approval-duration requirements.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Enzyme and Metabolic Disorder TherapiesThis policy governs MassHealth UPPL medical-benefit coverage, prior authorization, and quantity-limit requirements for enzyme and metabolic disorder therapies in members with specified lysosomal, metabolic, immune, or plasminogen disorders.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Enzyme and Metabolic Disorder Therapies: Adzynma (ADAMTS13, recombinant-krhn)This policy governs prior authorization for Adzynma under the MassHealth UPPL for members receiving medical-benefit therapy and establishes eligibility, documentation, dosing, prescriber, and continuation requirements for congenital thrombotic thrombocytopenic purpura.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Enzyme and Metabolic Disorder Therapies: Avlayah (tividenofusp alfa-eknm)This policy governs MassHealth prior authorization under the medical benefit for continued treatment with Avlayah for eligible members with Hunter syndrome, including members new to the plan and members continuing established therapy.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Erythropoiesis-Stimulating AgentsThis policy governs prior authorization for Aranesp, Epogen, Procrit, and Retacrit under the MassHealth UPPL medical benefit. Coverage is limited to specified anemia-related diagnoses and requires diagnosis-specific clinical criteria, documentation, and authorization durations.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Glaucoma Agents iDose TR (travoprost intracameral implant)This policy governs MassHealth prior authorization and continuation or recertification of iDose TR (travoprost intracameral implant) through the medical benefit. It applies to members receiving treatment for open-angle glaucoma or ocular hypertension and specifies clinical, documentation, safety, and timing requirements.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Herceptin Products (Trastuzumab)This policy governs prior authorization for trastuzumab reference, biosimilar, and subcutaneous products provided under the medical benefit for MassHealth members. It establishes coverage criteria for HER2-overexpressing breast cancer, HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, and RAS wild-type HER2-positive unresectable or metastatic colorectal cancer.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Loargys (pegzilarginase-nbln) — Continuation of TherapyThis policy governs prior authorization for Loargys under the medical benefit for MassHealth UPPL members with Arginase 1 Deficiency, including documentation, clinical eligibility, continuation, dosing, and authorization-duration requirements.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Lumvoa (veligrotug-vvze) Continuation TherapyThis policy governs prior authorization and continuation of Lumvoa (veligrotug-vvze) for members with thyroid eye disease under the MassHealth UPPL. It applies to medical-benefit coverage and notes that Lumvoa is also available through the pharmacy benefit.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Lupus Agents: Benlysta (belimumab) and Saphnelo (anifrolumab-fnia) VialsThis policy governs prior authorization for Benlysta intravenous vial therapy under the MassHealth medical benefit for members with systemic lupus erythematosus or lupus nephritis. It also presents related criteria for Saphnelo vial therapy and applies to providers requesting coverage.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Neuromuscular Blockers: Botox, Daxxify, Dysport, Myobloc, and XeominThis policy governs MassHealth prior authorization for Botox, Daxxify, Dysport, Myobloc, and Xeomin under the medical benefit, including covered indications, dose limits, prescriber requirements, prerequisite therapies, and continuation criteria. The medications are also available under the pharmacy benefit and require review under the applicable MassHealth pharmacy policy.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Osteoporosis Agents: Prolia and Denosumab BiosimilarsThis policy governs prior authorization for Prolia and denosumab biosimilars under the MassHealth medical benefit for osteoporosis, glucocorticoid-induced osteoporosis, and bone-mass preservation during selected high-risk cancer therapies. Clinical documentation, preferred-product sequencing, and renewal criteria apply.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Osteoporosis Agents: Xgeva (denosumab) and Denosumab BiosimilarsThis policy governs medical-benefit prior authorization for denosumab products for MassHealth members, including prevention of skeletal-related events associated with bone metastases or multiple myeloma, treatment of hypercalcemia of malignancy, and treatment of giant cell tumor of bone.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Pombiliti (cipaglucosidase alfa-atga) Continuation TherapyMassHealth managed Medicaid prior authorization for Pombiliti administered through the medical benefit for adults with late-onset Pompe disease who meet applicable clinical and treatment criteria.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Prostate Cancer Agents: Jevtana (cabazitaxel) — Continuation of TherapyThis policy governs prior authorization for Jevtana (cabazitaxel) administered under the medical benefit for MassHealth members with metastatic castration-resistant prostate cancer. It establishes documentation requirements for members new to the plan, clinical criteria for authorization, and approval duration.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and RomidepsinThis clinical policy governs prior authorization for Istodax and related T-cell lymphoma agents under the MassHealth unified preferred product list and the medical benefit for members with cutaneous or peripheral T-cell lymphoma and related hematologic malignancies.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Tepezza (teprotumumab-trbw) Continuation TherapyThis policy governs prior authorization and continuation coverage for Tepezza under the medical benefit for adults with thyroid eye disease, including documentation, clinical criteria, dosing limits, and reauthorization requirements.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-04Treatment of OsteoporosisThis policy governs prior authorization for medically administered Evenity (romosozumab-aqqg) under the MassHealth UPPL medical benefit. It applies to treatment of osteoporosis in postmenopausal women and, off-label, in biologic males or members assigned male sex at birth who meet specified clinical and prior-treatment criteria.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-01Adalimumab ProductsThis policy governs prior authorization and pharmacy coverage for preferred adalimumab products under the Commercial/Exchange pharmacy benefit. It establishes diagnosis-specific initial authorization criteria, continuation requirements, quantity limits, approval durations, and specialty-pharmacy dispensing requirements for members with rheumatoid arthritis and other labeled inflammatory conditions.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-01Attention Deficit Hyperactivity Disorder (ADHD) Stimulants Step TherapyThis policy governs commercial/Exchange pharmacy-benefit coverage for stimulant medications used primarily to treat attention-deficit/hyperactivity disorder. First-line agents are available without prior authorization, while second-line agents require specified prior use, clinical exception criteria, or documentation for members who are new to the plan.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-01Dry Eye Disease: Miebo, Restasis, Restasis Multidose, Tryptyr, and XiidraThis policy governs prior authorization coverage under the commercial/Exchange pharmacy benefit for Miebo, Restasis, Restasis Multidose, Tryptyr, and Xiidra for members with dry eye disease. It establishes initial authorization, continuation, documentation, and authorization-duration requirements.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-01Entyvio SC (vedolizumab) Coverage CriteriaPrior authorization and pharmacy coverage for Entyvio SC in adults with moderately to severely active ulcerative colitis or Crohn's disease under the commercial/Exchange pharmacy benefit.All Mass General Brigham Health Plan updates
- Prior AuthClinical/Medical PolicyEff. 2027-01-01Gender Affirming ProceduresMedical-necessity and prior-authorization requirements for gender-affirming surgeries, hair removal, fertility preservation, speech therapy, and vocal cord surgery across Medicare Advantage, ACO, One Care/SCO, Commercial, and Qualified Health Plan members.All Mass General Brigham Health Plan updates
Tool Description
Search Mass General Brigham Health Planprior authorization policies by drug name, procedure, or policy title. Results include any policy that mentions prior authorization requirements (drug coverage criteria, imaging guidelines, site-of-service rules) not just documents titled “prior authorization.” Every result links to a full policy page with clinical criteria, covered billing codes, documentation requirements, and effective dates.
Filter by payer, specialty, policy type, or effective year; or search directly for a drug (“Wegovy,” “Ozempic”), a procedure (“MRI,” “knee arthroplasty”), or a policy number.
Coverage spans 110+ payers. Jump straight to the busiest prior-auth publishers: UnitedHealthcare, Cigna, Aetna, Anthem, and Centene. You can also browse the full policy updates feed.
Pair a prior-auth search with the billing code lookup to confirm the CPT or J-code on the claim, the payer lookup for plan footprint, and payer profiles for contacts and coverage context.
FAQ
Prior Authorization by Payer
Go deeper
Explore OpenPayer Data
Prior auth requirements change all the time. Keep up with every payer policy update in the live policy feed, or browse payers with prior authorization policies.
Toolbox
More OpenPayer Tools
- Billing Code LookupSearch CPT, HCPCS, J-codes, DRG, and dental codes by number or procedure name.
- Billing Code Reimbursement RatesBuild a reimbursement rate report across any mix of billing codes and states, comparing commercial payers against Medicare.
- Payer Comparison DashboardPick 2-5 payers to compare market share, premium, and membership by region, all at once.
- Facility Comparison DashboardPick 2-6 hospital facility types (or add a specific hospital) to compare facility count, revenue, net income, and Medicare/Medicaid payer mix by region, all at once.
- Healthcare Provider & Facility LookupFind hospitals and healthcare facilities by name, taxonomy, facility type, ownership, or state.
- Health Insurance Payer LookupSearch national health insurance payers and health plans by name and state presence.
- Provider Taxonomy Code LookupSearch NUCC taxonomy codes by code, specialty, grouping, or classification.
- CPT Modifier LookupSearch CPT modifiers by code or name — descriptions, when to use them, and payer policy context.
- Timely Filing LookupFind payer timely filing policies: claim deadlines, corrected claim windows, and appeal timeframes.
- Coverage Criteria LookupSearch payer coverage criteria and medical necessity requirements by drug, procedure, or payer.
- Payer Contact DirectoryClaims, prior authorization, provider services, and appeals contacts for health insurance payers.
Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.